(Q40392451)

20 September 2017

Signaling via the anti-CD30 mAb SGN-30 sensitizes Hodgkin's disease cells to conventional chemotherapeutics (English)

1 reference

20 September 2017

1 reference

Cerveny CG

1

1 reference

20 September 2017

Law CL

2

1 reference

20 September 2017

McCormick RS

3

1 reference

20 September 2017

Lenox JS

4

1 reference

20 September 2017

Hamblett KJ

5

1 reference

20 September 2017

Westendorf LE

6

1 reference

20 September 2017

Yamane AK

7

1 reference

20 September 2017

Petroziello JM

8

1 reference

20 September 2017

Francisco JA

9

1 reference

20 September 2017

Wahl AF

10

1 reference

20 September 2017

1 September 2005

1 reference

20 September 2017

1 reference

20 September 2017

19

1 reference

20 September 2017

9

1 reference

20 September 2017

1648-1655

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.leu.2403884

20 September 2017

0 references

cites work

Interleukin 13 and interleukin 13 receptor are frequently expressed by Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403884

CD30 and CD117 (c-kit) used in combination are useful for distinguishing embryonal carcinoma from seminoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403884

cAC10-vcMMAE, an anti-CD30–monomethyl auristatin E conjugate with potent and selective antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403884

Cytoplasmic aggregation of TRAF2 and TRAF5 proteins in the Hodgkin-Reed-Sternberg cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403884

Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403884

Rituximab-mediated sensitization of B-non-Hodgkin's lymphoma (NHL) to cytotoxicity induced by paclitaxel, gemcitabine, and vinorelbine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403884

Developing drugs to decrease the toxicity of chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403884

Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403884

Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK/p38 and mitochondrial death pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403884

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403884

Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403884

Inhibition of NF-kappaB essentially contributes to arsenic-induced apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403884

Nuclear factor kappaB-dependent gene expression profiling of Hodgkin's disease tumor cells, pathogenetic significance, and link to constitutive signal transducer and activator of transcription 5a activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403884

Cloning of mouse genomic ribosomal protein L6 gene and analysis of its promoter.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403884

Outpatient-based ifosfamide, carboplatin and etoposide (ICE) chemotherapy in transplant-eligible patients with non-Hodgkin’s lymphoma and Hodgkin’s disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403884

CD30-mediated cell cycle arrest associated with induced expression of p21(CIP1/WAF1) in the anaplastic large cell lymphoma cell line Karpas 299.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403884

Signal transduction in anaplastic large cell lymphoma cells (ALCL) mediated by the tumor necrosis factor receptor CD30.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403884

Cell-type-specific responses to chemotherapeutics in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403884

p53-independent induction of p21(waf1/cip1) contributes to the activation of caspases in GTP-depletion-induced apoptosis of insulin-secreting cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403884

AKT/PKB phosphorylation of p21Cip/WAF1 enhances protein stability of p21Cip/WAF1 and promotes cell survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403884

Chemosensitization and radiosensitization of human cancer by antisense anti-MDM2 oligonucleotides: in vitro and in vivo activities and mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403884

Combination of the human anti-CD30 antibody 5F11 with cytostatic drugs enhances its antitumor activity against Hodgkin and anaplastic large cell lymphoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403884

Hodgkin and Reed-Sternberg cells harbor alterations in the major tumor suppressor pathways and cell-cycle checkpoints: analyses using tissue microarrays

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403884

Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403884

inferred from DOI database lookup

7 January 2021

based on heuristic

The human anti-CD30 antibody 5F11 shows in vitro and in vivo activity against malignant lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403884

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/SJ.LEU.2403884

1 reference

Dimensions Publication ID

20 September 2017

0 references

1 reference